Abstract
It has been recognized that Gastrodia elata Bl (GE), an oriental herb medicine, ameliorates various neurological disorders, that GE modulates the monoaminergic and GABAergic systems, and that GE possess antioxidant activities. We examined whether GE affects methamphetamine (MA)-induced striatal dopaminergic toxicity in mice. Treatment with MA (7.5 mg/kg, i.p. × 4) resulted in significant decreases in behavioural activity (as shown by locomotor activity and rota rod performance), dopamine level, tyrosine hydroxylase (TH) activity, and TH protein expression (as evaluated by immunocytochemistry and western blot analysis). In addition, MA treatment showed significant increases in lipid peroxidation [as evaluated by 4-hydroxy-2-nonenal (4-HNE) expression and malondialdehyde formation], protein oxidation (as shown by protein carbonyl expression and its formation), and reactive oxygen species (ROS) formation. Treatment with GE significantly attenuates MA-induced behavioural and dopaminergic impairments, and oxidative stresses in a dose-dependent manner. Our results suggest that GE treatment shows anti-dopaminergic effects in response to MA insult via, at least in part, inhibiting oxidative stresses in the striatum of the mice.
Keywords: Gastrodia elata Bl, methamphetamine, dopamine, oxidative stress, GABA receptor, DOPAC, Dopaminergic Toxicity, Tryosine Hydroxylase, Oxidative Burdens
Current Neuropharmacology
Title: Gastrodia Elata Bl Attenuates Methamphetamine-Induced Dopaminergic Toxicity Via Inhibiting Oxidative Burdens
Volume: 9 Issue: 1
Author(s): E.-J. Shin, J.-H. Bach, T.-T. L. Nguyen, X.-K. T. Nguyen, B.-D. Jung, K.-W. Oh, M. J. Kim, S. K. Ko, C. G. Jang, S. F. Ali and H.-C. Kim
Affiliation:
Keywords: Gastrodia elata Bl, methamphetamine, dopamine, oxidative stress, GABA receptor, DOPAC, Dopaminergic Toxicity, Tryosine Hydroxylase, Oxidative Burdens
Abstract: It has been recognized that Gastrodia elata Bl (GE), an oriental herb medicine, ameliorates various neurological disorders, that GE modulates the monoaminergic and GABAergic systems, and that GE possess antioxidant activities. We examined whether GE affects methamphetamine (MA)-induced striatal dopaminergic toxicity in mice. Treatment with MA (7.5 mg/kg, i.p. × 4) resulted in significant decreases in behavioural activity (as shown by locomotor activity and rota rod performance), dopamine level, tyrosine hydroxylase (TH) activity, and TH protein expression (as evaluated by immunocytochemistry and western blot analysis). In addition, MA treatment showed significant increases in lipid peroxidation [as evaluated by 4-hydroxy-2-nonenal (4-HNE) expression and malondialdehyde formation], protein oxidation (as shown by protein carbonyl expression and its formation), and reactive oxygen species (ROS) formation. Treatment with GE significantly attenuates MA-induced behavioural and dopaminergic impairments, and oxidative stresses in a dose-dependent manner. Our results suggest that GE treatment shows anti-dopaminergic effects in response to MA insult via, at least in part, inhibiting oxidative stresses in the striatum of the mice.
Export Options
About this article
Cite this article as:
Shin E.-J., Bach J.-H., L. Nguyen T.-T., T. Nguyen X.-K., Jung B.-D., Oh K.-W., J. Kim M., K. Ko S., G. Jang C., F. Ali S. and Kim H.-C., Gastrodia Elata Bl Attenuates Methamphetamine-Induced Dopaminergic Toxicity Via Inhibiting Oxidative Burdens, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016967
DOI https://dx.doi.org/10.2174/157015911795016967 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Current Medicinal Chemistry On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Current Acetylcholinesterase-Inhibitors: A Neuroinformatics Perspective
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Biochemical Markers and Risk Factors of Alzheimers Disease
Current Alzheimer Research Pharmacologic Treatment of Rapid Ejaculation: Levels of Evidence-Based Review
Current Clinical Pharmacology Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review
Current Drug Discovery Technologies What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial
CNS & Neurological Disorders - Drug Targets CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery